Figure 1.
The receiver operating characteristic (ROC) curves of the NLR and PLR in patients with unresectable HCC who received atezolizumab plus bevacizumab. The area under the curves (AUC) for NLR (A) and for PLR (B).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.